Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenzilumab - Humanigen

Drug Profile

Lenzilumab - Humanigen

Alternative Names: Humaneered® anti-human GM-CSF monoclonal Antibody; KB-003

Latest Information Update: 11 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Developer Humanigen; KaloBios Pharmaceuticals; Kite Pharma; National Institute of Allergy and Infectious Diseases; Peter MacCallum Cancer Centre
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cytokine release syndrome
  • Phase III COVID 2019 infections
  • Phase I/II B-cell lymphoma; Drug hypersensitivity
  • Preclinical Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Chronic myelomonocytic leukaemia; Solid tumours
  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 08 Oct 2021 Lenzilumab licensed to Clinigen in Austria, Bulgaria, Croatia, Cyprus, Denmark, Estonia, France, Greece, Ireland, Lithuania, Luxembourg, Netherlands, Portugal, Spain, Sweden, and Switzerland for the treatment of COVID-2019 infections
  • 29 Sep 2021 Biomarkers information updated
  • 29 Sep 2021 Efficacy results from a phase III study in COVID-19 infections presented at the at IDWeek 2021 .
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top